NEW DRUGS FOR THE TREATMENT OF CANCER
PharmaEngine
We Race With You
DISCOVER MORE
CANCER TREATMENT PRODUCTS
ONIVYDE
A Revolutionary Durg
DISCOVER ONIVYDE
NEW CONCEPTS FOR RADIOTHERAPY
Groundbreaking
Cancer Treatment
DISCOVER PEP503
History<br> &<br> Milestones<br>
History
&
Milestones
Onivyde
Onivyde

PharmaEngine and Nanobiotix to Terminate Asia-Pacific Exclusive License and Collaboration Agreement for NBTXR3

PharmaEngine, Inc. Announces First Results for PEP503(NBTXR3) in Rectal Cancer Study at ASCO-GI 2021

PharmaEngine, Inc. and Sentinel Oncology Limited Enter into an Exclusive Collaboration and License Agreement for SOL-578, a Chk1 inhibitor
PEP503
R&D Pipeline
Events & Presentations
Organization
Our Partners
Contact Us
© 2020 PharmaEngine Inc.
Go To Top